Quoin Pharmaceuticals, Ltd.
Business
Quoin Pharmaceuticals, Ltd. is a late-stage clinical specialty pharmaceutical company developing therapeutic products for rare and orphan diseases with limited or no approved treatments. The company's lead product, QRX003, is a topical lotion under pivotal clinical testing for Netherton Syndrome and Peeling Skin Syndrome, with investigator-initiated studies ongoing in multiple countries. Additional pipeline candidates include QRX008 (under option for scleroderma) and QRX009 (novel topical rapamycin formulations for rare skin and vascular conditions). Quoin operates commercial partnerships spanning 61 countries and maintains research agreements with academic institutions to access licensed intellectual property.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| General and administrative | 6 | 6 | 6 | 7 | 4 | |
| Research and development | 10 | 4 | 3 | 3 | 2 | |
| Total operating expenses | 16 | 10 | 9 | 9 | 6 | |
| Unrealized gain | −3,980 | −7,502 | 2,683 | −1,307 | — | |
| Realized and accrued interest income | −482,081 | −558,491 | — | — | — | |
| Total other income | −486,061 | −565,993 | −691,931 | 123,792 | 15 | |
| Net loss | −16 | −9 | −9 | −9 | −21 | |
| Foreign currency translation | −613 | — | — | — | — | |
| Total other comprehensive loss | −613 | — | — | — | — | |
| Comprehensive loss | −16 | −9 | — | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 4 | 2 | 3 | 7 | |
| Investments | 15 | 10 | — | — | — | |
| Prepaid expenses and other current assets | 1 | 869,126 | 591,034 | 516,584 | — | |
| Total current assets | 20 | 15 | 11 | 13 | 8 | |
| Prepaid expenses - long term | — | 300,000 | 300,000 | 383,390 | 300,000 | |
| Intangible assets, net | 383,334 | 483,334 | 583,334 | 704,561 | 808,604 | |
| Total assets | 20 | 16 | 12 | 14 | 9 | |
| Accounts payable | 1 | 905,704 | 526,523 | 605,600 | 923,239 | |
| Accrued expenses | 3 | 2 | 1 | 1 | 2 | |
| Accrued interest and financing expense | 1 | 1 | — | — | — | |
| Due to officers - short term | 600,000 | 600,000 | 600,000 | 600,000 | — | |
| Total current liabilities | 6 | 4 | 4 | 4 | 5 | |
| Due to officers - long term | 2 | 2 | 3 | 4 | — | |
| Total liabilities | 7 | 7 | 7 | 7 | 9 | |
| Commitments and contingencies | — | — | — | — | — | |
| Ordinary shares, no par value per share, 5,000,000,000 and 100,000,000 ordinary shares authorized at December 31, 2025 and December 31, 2024, respectively - 52,441,360 (1,498,325 ADS's) ordinary shares issued and outstanding at December 31, 2025 and 8,948,164 (255,661 ADS's) ordinary shares issued and outstanding at December 31, 2024 | 0 | 0 | 0 | 0 | — | |
| Accumulated other comprehensive loss | −613 | — | — | — | — | |
| Additional paid in capital | 84 | 64 | 52 | 48 | 32 | |
| Accumulated deficit | −71 | −55 | −46 | −38 | −28 | |
| Total shareholders' equity | 13 | 9 | 6 | 7 | 657,032 | |
| Total liabilities and shareholders' equity | 20 | 16 | 12 | 14 | 9 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −16 | −9 | −9 | −9 | −21 | |
| Stock based compensation | 1 | 1 | 1 | 764,007 | — | |
| Amortization of intangibles | 100,000 | 100,000 | 104,000 | 104,000 | 104,043 | |
| Realized and unrealized gain and accrued interest on investments | −215,855 | −251,590 | — | — | — | |
| Increase (decrease) in accounts payable and accrued expenses | 1 | 275,955 | 53,924 | — | — | |
| Decrease in prepaid expenses and other assets | −92,848 | −278,092 | 41,523 | 123,455 | −715,474 | |
| Net cash used in operating activities | −14 | −8 | −8 | −8 | −6 | |
| Purchase of investments | −12 | −17 | −18 | −10 | — | |
| Proceeds from redemption of investments | 8 | 15 | 20 | — | — | |
| Net cash used by investing activities | −4 | −2 | 2 | −10 | −625,000 | |
| Payment of amounts due to officers | −600,000 | −600,000 | −600,000 | −599,999 | −304,466 | |
| Proceeds from sale of equity securities, net | 19 | 12 | — | — | — | |
| Net cash provided by financing activities | 18 | 11 | 5 | 14 | 14 | |
| Effect of foreign exchange rate on changes on cash | −613 | — | — | — | — | |
| Net change in cash and cash equivalents: | 194,753 | 1 | — | — | — | |
| Offering expenses associated with warrant modification | — | 2 | 238,231 | 491,601 | — | |
| Accrued offering expenses included in additional paid in capital | 40,870 | 323,497 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Quoin Pharmaceuticals, Ltd.'s CIK number?
Quoin Pharmaceuticals, Ltd.'s SEC CIK number is 0001671502 (1671502). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Quoin Pharmaceuticals, Ltd.'s SEC filings?
All of Quoin Pharmaceuticals, Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Quoin Pharmaceuticals, Ltd. last report earnings?
Quoin Pharmaceuticals, Ltd. (QNRX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-057140). This is Quoin Pharmaceuticals, Ltd.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Quoin Pharmaceuticals, Ltd.'s most recent earnings 8-K?
Quoin Pharmaceuticals, Ltd.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-057140. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Quoin Pharmaceuticals, Ltd.'s latest earnings 8-K →
Look up any company's CIK number →